The companies entered into a definitive agreement for the acquisition in June. It was previously reported that Mindray would pay $35.5 million for the controlling stake in Dragonbio.
Mindray Medical, through its subsidiary, Shenzhen Mindray, develops and manufactures medical devices worldwide. Dragonbio is a medical orthopedic products provider that specializes in trauma, spine, joint and other surgical products, and sells these products solely in China.
Mindray Medical is headquartered in Shenzhen, China.
Related Articles on Company Acquisitions:
STERIS to Acquire US Endoscopy for $270M
Henry Schein Completes Three Acquisitions
Accuray to Acquire Morphormics for $5.7M
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.